S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
What’s At Stake In April is Shocking (Ad)pixel
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
What’s At Stake In April is Shocking (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
What’s At Stake In April is Shocking (Ad)pixel
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
What’s At Stake In April is Shocking (Ad)pixel
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
What’s At Stake In April is Shocking (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
What’s At Stake In April is Shocking (Ad)pixel
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
What’s At Stake In April is Shocking (Ad)pixel
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
What’s At Stake In April is Shocking (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
What’s At Stake In April is Shocking (Ad)pixel
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
What’s At Stake In April is Shocking (Ad)pixel
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
What’s At Stake In April is Shocking (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
What’s At Stake In April is Shocking (Ad)pixel
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
Positive News Sentiment  
NASDAQ:TARS

Tarsus Pharmaceuticals - TARS Stock Forecast, Price & News

$12.57
-0.09 (-0.71%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$12.44
▼
$12.95
50-Day Range
$11.92
▼
$16.27
52-Week Range
$10.80
▼
$19.66
Volume
110,085 shs
Average Volume
74,724 shs
Market Capitalization
$336.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.00

Tarsus Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
226.2% Upside
$41.00 Price Target
Short Interest
Bearish
5.40% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$822,740 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.82) to ($3.01) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

512th out of 996 stocks

Biological Products, Except Diagnostic Industry

90th out of 165 stocks

See Top Rated MarketRank™ Stocks Here

TARS stock logo

About Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Receive TARS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TARS Stock News Headlines

March 22, 2023 | americanbankingnews.com
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Sells $10,557.60 in Stock
March 17, 2023 | finance.yahoo.com
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Is Expected To Breakeven In The Near Future
April 2, 2023 | Vantage Point (Ad)
What’s At Stake In April is Shocking
The Fed will be meeting on a topic that could change trading forever, and the decision could come as soon as the end of April. But by taking the smartest approach now, you can help shield your assets and work toward your trading goals. Time, as always, is of the essence. Click on this link to see what you need to do right away. pixel
March 15, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM), Tarsus Pharmaceuticals (TARS) and Decibel Therapeutics (DBTX)
March 14, 2023 | finanznachrichten.de
Tarsus Pharmaceuticals, Inc: Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements
March 14, 2023 | msn.com
Tarsus Pharmaceuticals GAAP EPS of -$2.52, revenue of $25.82M
March 13, 2023 | finance.yahoo.com
Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements
February 24, 2023 | finance.yahoo.com
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insiders placed bullish bets worth US$1.6m in the last 12 months
April 2, 2023 | Legacy Research (Affiliate) (Ad)
Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
January 24, 2023 | seekingalpha.com
Tarsus Pharma: Excellent Data, Nice Execution, Unclear Market Potential
December 22, 2022 | finanznachrichten.de
Tarsus Pharmaceuticals, Inc: Tarsus Added to NASDAQ Biotechnology Index
December 15, 2022 | finance.yahoo.com
Tarsus Pharma Touts Positive Data For Experimental Drug For Tick-Borne Disease
December 15, 2022 | finance.yahoo.com
Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease
December 8, 2022 | finance.yahoo.com
Institutional investors own a significant stake of 41% in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
November 11, 2022 | finance.yahoo.com
Tarsus Pharmaceuticals Third Quarter 2022 Earnings: US$0.84 loss per share (vs US$0.76 loss in 3Q 2021)
November 9, 2022 | msn.com
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Misses Revenue Estimates
November 9, 2022 | finance.yahoo.com
Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements
October 25, 2022 | finance.yahoo.com
Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting
October 17, 2022 | finance.yahoo.com
Tarsus Pharmaceuticals (NASDAQ:TARS) investors are sitting on a loss of 40% if they invested a year ago
October 11, 2022 | finance.yahoo.com
Tarsus Announces Transition Plans for Board of Directors
October 6, 2022 | finance.yahoo.com
Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair
September 29, 2022 | finance.yahoo.com
Tarsus Launches “Look at the Lids” Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis
September 27, 2022 | finance.yahoo.com
Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings
September 17, 2022 | finance.yahoo.com
The Chief Medical Advisor & Director of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), Elizabeth Lin, Just Bought A Few More Shares
September 7, 2022 | finance.yahoo.com
Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitis
August 24, 2022 | reuters.com
Tarsus Pharmaceuticals Inc
August 14, 2022 | nasdaq.com
The Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
See More Headlines
Receive TARS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TARS Company Calendar

Last Earnings
11/09/2021
Today
4/02/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TARS
CUSIP
N/A
CIK
1819790
Web
www.tarsusrx.com
Phone
949-409-9820
Fax
N/A
Employees
46
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$41.00
High Stock Price Forecast
$43.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+226.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.55)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-62,090,000.00
Net Margins
-324.99%
Pretax Margin
-240.53%
Return on Equity
-32.41%
Return on Assets
-27.64%

Debt

Debt-to-Equity Ratio
0.10
Current Ratio
14.61
Quick Ratio
14.61

Sales & Book Value

Annual Sales
$25.82 million
Price / Sales
13.01
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.23 per share
Price / Book
1.74

Miscellaneous

Outstanding Shares
26,730,000
Free Float
17,889,000
Market Cap
$336.00 million
Optionable
Not Optionable
Beta
0.69

Key Executives

  • Dr. Bobak R. Azamian M.D.
    Co-Founder, Pres, CEO & Chairman
  • Dr. Bryan Wahl J.D. (Age 44)
    M.D., Gen. Counsel & Corp. Sec.
    Comp: $545.52k
  • Ms. Dianne C. Whitfield M.S.W. (Age 45)
    Chief HR Officer
    Comp: $578.9k
  • Dr. Elizabeth Yeu Lin M.D. (Age 44)
    Chief Medical Advisor & Director
    Comp: $240k
  • Dr. D. Michael Ackermann Ph.D. (Age 40)
    Consultant
    Comp: $130k
  • Mr. Leonard M. Greenstein J.D. (Age 46)
    Chief Financial Officer
  • Dr. Seshadri Neervannan Ph.D. (Age 54)
    Chief Operating Officer
  • Mr. David Nakasone
    Head of Investor Relations
  • Ms. Adrienne Kemp
    Sr. Director of Corp. Communications
  • Mr. Matthew Rossen M.B.A. (Age 45)
    VP of Marketing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













TARS Stock - Frequently Asked Questions

Should I buy or sell Tarsus Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tarsus Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TARS shares.
View TARS analyst ratings or view top-rated stocks.

What is Tarsus Pharmaceuticals' stock price forecast for 2023?

2 Wall Street research analysts have issued twelve-month target prices for Tarsus Pharmaceuticals' stock. Their TARS share price forecasts range from $40.00 to $43.00. On average, they anticipate the company's stock price to reach $41.00 in the next year. This suggests a possible upside of 226.2% from the stock's current price.
View analysts price targets for TARS or view top-rated stocks among Wall Street analysts.

How have TARS shares performed in 2023?

Tarsus Pharmaceuticals' stock was trading at $14.66 at the beginning of 2023. Since then, TARS shares have decreased by 14.3% and is now trading at $12.57.
View the best growth stocks for 2023 here.

When is Tarsus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our TARS earnings forecast.

How were Tarsus Pharmaceuticals' earnings last quarter?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) announced its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.76) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by $0.34. The firm earned $1.24 million during the quarter, compared to analysts' expectations of $1 million. Tarsus Pharmaceuticals had a negative trailing twelve-month return on equity of 32.41% and a negative net margin of 324.99%.

What ETFs hold Tarsus Pharmaceuticals' stock?

ETFs with the largest weight of Tarsus Pharmaceuticals (NASDAQ:TARS) stock in their portfolio include Invesco Raymond James SB-1 Equity ETF (RYJ), ALPS Medical Breakthroughs ETF (SBIO), Principal Healthcare Innovators ETF (BTEC) and Invesco Nasdaq Biotechnology ETF (IBBQ) and

When did Tarsus Pharmaceuticals IPO?

(TARS) raised $80 million in an initial public offering on Friday, October 16th 2020. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James acted as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers.

What is Tarsus Pharmaceuticals' stock symbol?

Tarsus Pharmaceuticals trades on the NASDAQ under the ticker symbol "TARS."

How do I buy shares of Tarsus Pharmaceuticals?

Shares of TARS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tarsus Pharmaceuticals' stock price today?

One share of TARS stock can currently be purchased for approximately $12.57.

How much money does Tarsus Pharmaceuticals make?

Tarsus Pharmaceuticals (NASDAQ:TARS) has a market capitalization of $336.00 million and generates $25.82 million in revenue each year. The company earns $-62,090,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

How can I contact Tarsus Pharmaceuticals?

The official website for the company is www.tarsusrx.com. The company can be reached via phone at 949-409-9820 or via email at ir@tarsusrx.com.

This page (NASDAQ:TARS) was last updated on 4/2/2023 by MarketBeat.com Staff